Current status of transcatheter interventional therapy of valve disease in China_West China Medical Journal

Authors：

 HAN Yaling , XU Kai

Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, Liaoning 110016, P. R. China;

Corresponding author：

HAN Yaling, Email: hanyalingnh@163.com

Keywords：

Transcatheter; Valve disease; Interventional therapy

DOI：

10.7507/1002-0179.202008110

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

In recent years, the transcatheter interventional therapy of valvular disease has been developed rapidly, and new therapeutic devices are emerging, which has become the first-line treatment in parallel with surgery. Although the interventional therapy of valve disease in China started relatively late, the development speed is relatively fast, and many remarkable achievements has been accomplished. This article will introduce the application of transcatheter intervention in valvular diseases in China, including aortic valve disease, mitral valve disease, pulmonary valve disease and tricuspid valve disease.

Citation： HAN Yaling, XU Kai. Current status of transcatheter interventional therapy of valve disease in China. West China Medical Journal, 2020, 35(9): 1035-1038. doi: 10.7507/1002-0179.202008110 Copy

1.	Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N EnglJ Med, 2016, 374(17): 1609-1620.
2.	Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med, 2017, 376(14): 1321-1331.
3.	Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol, 2017, 70(2): 252-289.
4.	Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2017, 38(36): 2739-2791.
5.	Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, 2019, 380(18): 1695-1705.
6.	Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, 2019, 380(18): 1706-1715.
7.	吴永健. VenusA-Valve 5年临床研究结果. (2020-07-31)[2020-08-11]. http://www.drvoice.cn/speaker/65328.
8.	Liao YB, Li YJ, Xiong TY, et al. Comparison of procedural, clinical and valve performance results of transcatheter aortic valve replacement in patients with bicuspid versus tricuspid aortic stenosis. Int J Cardiol, 2018, 254: 69-74.
9.	Jilaihawi H, Wu Y, Yang Y, et al. Morphological characteristics of severe aortic stenosis in China: imaging corelab observations from the first Chinese transcatheter aortic valve trial. Catheter Cardiovasc Interv, 2015, 85(Suppl 1): 752-761.
10.	中华医学会心血管病学分会结构性心脏病学组. 经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄的中国专家建议. 中华心血管病杂志, 2020, 48(8): 634-640.
11.	Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med, 2011, 364(15): 1395-1406.
12.	Wang S, Meng X, Luo Z, et al. Transapical beating-heart mitral valve repair using a novel artificial chordae implantation system. Ann Thorac Surg, 2018, 106(5): e265-e267.
13.	Pan W, Pan C, Jilaihawi H, et al. A novel user-friendly transcatheter edge-to-edge mitral valve repair device in a porcine model. Catheter Cardiovasc Interv, 2019, 93(7): 1354-1360.
14.	王建安. 二尖瓣介入治疗新进展. (2020-09-01)[2020-09-02]. http://www.drvoice.cn/speaker/71602.
15.	Morgan G, Prachasilchai P, Promphan W, et al. Medium-term results of percutaneous pulmonary valve implantation using the Venus P-valve: international experience. EuroIntervention, 2019, 14(13): 1363-1370.
16.	Zhou D, Pan W, Jilaihawi H, et al. A self-expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one-year results. EuroIntervention, 2019, 14(13): 1371-1377.
17.	Lu FL, Ma Y, An Z, et al. First-in-man experience of transcatheter tricuspid valve replacement with LuX-Valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv, 2020, 13(13): 1614-1616.
18.	林心平, 王建安. 中国心脏瓣膜病介入治疗的现状与进展. 心电与循环, 2019, 38(5): 353-356.

1. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N EnglJ Med, 2016, 374(17): 1609-1620.
2. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med, 2017, 376(14): 1321-1331.
3. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol, 2017, 70(2): 252-289.
4. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J, 2017, 38(36): 2739-2791.
5. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, 2019, 380(18): 1695-1705.
6. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, 2019, 380(18): 1706-1715.
7. 吴永健. VenusA-Valve 5年临床研究结果. (2020-07-31)[2020-08-11]. http://www.drvoice.cn/speaker/65328.
8. Liao YB, Li YJ, Xiong TY, et al. Comparison of procedural, clinical and valve performance results of transcatheter aortic valve replacement in patients with bicuspid versus tricuspid aortic stenosis. Int J Cardiol, 2018, 254: 69-74.
9. Jilaihawi H, Wu Y, Yang Y, et al. Morphological characteristics of severe aortic stenosis in China: imaging corelab observations from the first Chinese transcatheter aortic valve trial. Catheter Cardiovasc Interv, 2015, 85(Suppl 1): 752-761.
10. 中华医学会心血管病学分会结构性心脏病学组. 经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄的中国专家建议. 中华心血管病杂志, 2020, 48(8): 634-640.
11. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med, 2011, 364(15): 1395-1406.
12. Wang S, Meng X, Luo Z, et al. Transapical beating-heart mitral valve repair using a novel artificial chordae implantation system. Ann Thorac Surg, 2018, 106(5): e265-e267.
13. Pan W, Pan C, Jilaihawi H, et al. A novel user-friendly transcatheter edge-to-edge mitral valve repair device in a porcine model. Catheter Cardiovasc Interv, 2019, 93(7): 1354-1360.
14. 王建安. 二尖瓣介入治疗新进展. (2020-09-01)[2020-09-02]. http://www.drvoice.cn/speaker/71602.
15. Morgan G, Prachasilchai P, Promphan W, et al. Medium-term results of percutaneous pulmonary valve implantation using the Venus P-valve: international experience. EuroIntervention, 2019, 14(13): 1363-1370.
16. Zhou D, Pan W, Jilaihawi H, et al. A self-expanding percutaneous valve for patients with pulmonary regurgitation and an enlarged native right ventricular outflow tract: one-year results. EuroIntervention, 2019, 14(13): 1371-1377.
17. Lu FL, Ma Y, An Z, et al. First-in-man experience of transcatheter tricuspid valve replacement with LuX-Valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv, 2020, 13(13): 1614-1616.
18. 林心平, 王建安. 中国心脏瓣膜病介入治疗的现状与进展. 心电与循环, 2019, 38(5): 353-356.

West China Medical Journal

Current status of transcatheter interventional therapy of valve disease in China

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content